Current Status of Immunotherapy for Lung Cancer and Future Perspectives

Ho Cheol Kim; Chang Min Choi

doi:10.4046/trd.2019.0039

Current Status of Immunotherapy for Lung Cancer and Future Perspectives

Tuberc Respir Dis (Seoul). 2020 Jan;83(1):14-19. doi: 10.4046/trd.2019.0039.

Authors

Ho Cheol Kim¹, Chang Min Choi^{1

2}

Affiliations

¹ Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
² Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. ccm@amc.seoul.kr.

Abstract

Lung cancer remains the most common cause of cancer-related deaths worldwide. Although there are many possible treatments, including targeted therapies such as epidermal growth factor receptor tyrosine kinase inhibitors and anaplastic lymphoma kinase inhibitors, new therapeutic strategies are needed to improve clinical outcomes. Immunotherapy through the use of immune checkpoint inhibitors has provided one of the most important breakthroughs in the management of solid tumors, including lung cancers, and has shown promising results in numerous clinical trials. This review will present the current status of immunotherapy for lung cancer and future perspectives on these treatments.

Keywords: Immunotherapy; Lung Neoplasms; Prognosis; Survival.

Publication types

Review